Singh Abhishek, Khanna Puneet, Sarkar Soumya
Department of Anaesthesia, Pain Medicine and Critical Care, All India Institute of Medical Sciences (AIIMS), Ansari Nagar, New Delhi, 110029 India.
Curr Anesthesiol Rep. 2021;11(2):101-106. doi: 10.1007/s40140-021-00439-4. Epub 2021 Mar 2.
This review instantiates the efficacy and safety of HFNC in the context of COVID-19 pandemic.
Globally, the healthcare system is facing an unprecedented crisis of resources due to the 2019 novel coronavirus disease (COVID-19) pandemic. Fever, cough, dyspnea, myalgia, fatigue, and pneumonia are the most common symptoms associated with it. The incidence of invasive mechanical ventilation in ICU patients ranges from 29.1 to 89.9%. Supplemental oxygen therapy is the main stay treatment for managing hypoxemic respiratory failure. The high-flow nasal cannula (HFNC) is a novel non-invasive strategy for better oxygenation and ventilation in critically ill patients. In this grim scenario, a reduction in mechanical ventilation by means of HFNC is of prime interest.
HFNC is considered an aerosol-generating intervention with the risk of viral aerosolization with a concern of potential nosocomial transmission of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2). However, there is no consensus regarding the use of HFNC in novel coronavirus-infected pneumonia (NCIP). HFNC seems to be an effective and safe treatment modality in acute respiratory failure with optimal settings and selection of ideal patients.
本综述阐述了高流量鼻导管吸氧（HFNC）在2019冠状病毒病（COVID-19）大流行背景下的疗效和安全性。
在全球范围内，由于2019新型冠状病毒病（COVID-19）大流行，医疗系统正面临前所未有的资源危机。发热、咳嗽、呼吸困难、肌痛、疲劳和肺炎是与之相关的最常见症状。重症监护病房（ICU）患者有创机械通气的发生率在29.1%至89.9%之间。补充氧疗是治疗低氧性呼吸衰竭的主要治疗手段。高流量鼻导管吸氧（HFNC）是一种用于改善危重症患者氧合和通气的新型无创策略。在这种严峻的情况下，通过HFNC减少机械通气备受关注。
HFNC被认为是一种可产生气溶胶的干预措施，存在病毒气溶胶化的风险，人们担心严重急性呼吸综合征冠状病毒2（SARS-CoV-2）可能会在医院内传播。然而，对于在新型冠状病毒感染肺炎（NCIP）中使用HFNC尚无共识。在急性呼吸衰竭中，通过优化设置并选择理想的患者，HFNC似乎是一种有效且安全的治疗方式。
